Nectar Social | $10,600,000 | (Jun 6, 2025)
Baobab | $13,702,071 | (Jun 6, 2025)
Signify Bio | $15,000,000 | (Jun 6, 2025)
Receptor Life Sciences, Inc.
United States
- Seattle, Washington
- 07/04/2022
- Series A
- $9,700,000
Receptor Life Sciences combines proven drug delivery technologies, compelling therapeutic candidates, and traditional drug development research practices to pursue a robust range of prescription drug treatments for CNS indications.
The delivery technologies, used in both oral and inhaled FDA-approved prescription drug products, represent a validated, strategic approach to overcoming traditional challenges of cannabinoid medicine. Receptor’s patented product candidates hold the potential to provide prescription treatments for a range of unmet medical needs, including anxiety and agitation in autism.
More information is at www.ReceptorLife.com.
- Industry Pharmaceutical Manufacturing
- Website https://receptorlife.com/
- LinkedIn https://www.linkedin.com/company/receptor-life-sciences-inc./
Related People
Mark TheeuwesFounder
United States -
Greater Philadelphia
Experienced Pharmaceutical Executive with a demonstrated history of working in all aspects of Clinical and Commercial Execution.
Voltrac | $2,286,772 | (Jun 6, 2025)
Rosebud | $6,000,000 | (Jun 6, 2025)
Allay Therapeutics | $57,500,000 | (Jun 6, 2025)
Impart Security | $12,000,000 | (Jun 6, 2025)
Flank | $10,000,000 | (Jun 6, 2025)
Obvio | $22,000,000 | (Jun 5, 2025)
Filament Syfter | $4,800,000 | (Jun 5, 2025)
Vivrelle | $62,000,000 | (Jun 5, 2025)
Sema4.ai | $25,000,000 | (Jun 5, 2025)